Current and Evolving Treatments of Genotype 1 Hepatitis C Virus

Gastroenterology Clinics of North America

Volumn 44, Issue 4, 2015, Pages 825-843

  Alqahtani, Saleh ^a   Sulkowski, Mark ^a  

^a JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

Cirrhosis; Hepatitis; Hepatitis C; Ledipasvir antiviral; Simeprevir; Sofosbuvir

Indexed keywords

ALFUZOSIN; AMIODARONE; ASUNAPREVIR PLUS BECLABUVIR PLUS DACLATASVIR; BOCEPREVIR; BUPRENORPHINE; CISAPRIDE; DACLATASVIR; DASABUVIR PLUS OMBITASVIR PLUS PARITAPREVIR PLUS RITONAVIR; DIGOXIN; ELBASVIR PLUS GRAZOPREVIR; FUROSEMIDE; GEMFIBROZIL; GS 9857; LEDIPASVIR; LEDIPASVIR PLUS SOFOSBUVIR; NALOXONE; PEGINTERFERON; PEGINTERFERON ALPHA; PLACEBO; PROTEINASE INHIBITOR; RADALBUVIR; RIBAVIRIN; RIFAMPICIN; SIMEPREVIR; SOFOSBUVIR; SOFOSBUVIR PLUS VELPATASVIR; TAMSULOSIN; TELAPREVIR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VEDROPREVIR; ANTIVIRUS AGENT;

ANEMIA; ASTHENIA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG METABOLISM; DRUG POTENTIATION; DRUG RESPONSE; DRUG SAFETY; DRUG TREATMENT FAILURE; FATIGUE; GENETIC POLYMORPHISM; GOUT; HEADACHE; HEMATOLOGIC DISEASE; HEMOLYTIC ANEMIA; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; INSOMNIA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MULTICENTER STUDY (TOPIC); NAUSEA; NONHUMAN; PATIENT ASSESSMENT; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; RELAPSE; REVIEW; SINUSITIS; COMBINATION DRUG THERAPY; DRUG ADMINISTRATION; DRUG INTERACTION; DRUG MONITORING; GENETICS; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; VIROLOGY;

ANTIVIRAL AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; DRUG MONITORING; DRUG THERAPY, COMBINATION; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS;

EID: 84947614518     PISSN: 08898553     EISSN: 15581942     Source Type: Journal    
DOI: 10.1016/j.gtc.2015.06.001     Document Type: Review

References (57)

1. Ghany M.G., Strader D.B., Thomas D.L., American Association for the Study of Liver Diseases, et al. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009, 49:1335-1374.
2. Fattovich G., Giustina G., Favarato S., et al. A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alfa interferon. J Hepatol 1996, 24:38-47.
3. Lotrich F.E. Psychiatric clearance for patients started on interferon-alpha-based therapies. Am J Psychiatry 2013, 170:592-597.
4. Lawitz E., Lalezari J.P., Hassanein T., et al. Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. Lancet Infect Dis 2013, 13:401-408.
5. Jacobson I.M., McHutchison J.G., Dusheiko G., ADVANCE Study Team, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011, 364:2405-2416.
6. Poordad F., McCone J., Bacon B.R., SPRINT-2 Investigators, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011, 364:1195-1206.
7. Manns M., Reesink H., Berg T., et al. Rapid viral response of once-daily TMC435 plus pegylated interferon/ribavirin in hepatitis C genotype-1 patients: a randomized trial. Antivir Ther 2011, 16:1021-1033.
8. Lawitz E., Mangia A., Wyles D., et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013, 368:1878-1887.
9. Gane E.J., Stedman C.A., Hyland R.H., et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med 2013, 368:34-44.
10. Spach DH, Kim HN. Medications to treat HCV. In: Spach DH, editor. Hepatitis C online. Available at: . Accessed May 15, 2015. http://www.hepatitisc.uw.edu/page/treatment/drugs.
11. Giroux S., Bilimoria D., Cadilhac C., et al. Discovery of thienoimidazole-based HCV NS5A inhibitors. Part 1: C2-symmetric inhibitors with diyne and biphenyl linkers. Bioorg Med Chem Lett 2015, 25:936-939.
12. Giroux S., Bilimoria D., Cadilhac C., et al. Discovery of thienoimidazole-based HCV NS5A inhibitors. Part 2: non-symmetric inhibitors with potent activity against genotype 1a and 1b. Bioorg Med Chem Lett 2015, 25:940-943.
13. Cammà C., Di Bona D., Craxì A. The impact of antiviral treatments on the course of chronic hepatitis C: an evidence-based approach. Curr Pharm Des 2004, 10:2123-2130.
14. Singal A.G., Waljee A.K., Shiffman M., et al. Meta-analysis: re-treatment of genotype I hepatitis C nonresponders and relapsers after failing interferon and ribavirin combination therapy. Aliment Pharmacol Ther 2010, 32:969-983.
15. Chen J., Florian J., Carter W., et al. Earlier sustained virologic response end points for regulatory approval and dose selection of hepatitis C therapies. Gastroenterology 2013, 144:1450-1455.
16. European Association for the Study of the Liver, Electronic address: easloffice@easloffice.eu EASL recommendations on treatment of hepatitis C 2015. J Hepatol 2015, 10.1016/j.jhep.2015.03.025.
17. AASLD/IDSA/IAS-USA. Recommendations for testing, managing, and treating hepatitis C. 2014. Updated April 9, 2015. Available at: . Accessed May 9, 2015. http://hcvguidelines.org.
18. Kowdley K.V., Lawitz E., Crespo I., et al. Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial. Lancet 2013, 381:2100-2107.
19. Sulkowski M.S., Jacobson I.M., Ghalib R., et al. Once-daily simeprevir (TMC435) plus sofosbuvir (GS-7977) with or without ribavirin in HCV genotype-1 prior null responders with metavir F0-2: COSMOS study subgroup analysis. Gastroenterol Hepatol (N Y) 2014, 9:1-18.
20. Lawitz E., Sulkowski M.S., Ghalib R., et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naïve patients: the COSMOS randomised study. Lancet 2014, 384:1756-1765.
21. Gane E.J., Stedman C.A., Hyland R.H., et al. Efficacy of nucleotide polymerase inhibitor sofosbuvir plus the NS5A inhibitor ledipasvir or the NS5B non-nucleoside inhibitor GS-9669 against HCV genotype 1 infection. Gastroenterology 2014, 146:736-743.e1.
22. Afdhal N., Zeuzem S., Kwo P., ION-1 Investigators, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014, 370:1889-1898.
23. Kowdley K.V., Gordon S.C., Reddy K.R., ION-3 Investigators, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 2014, 370:1879-1888.
24. Bourlière M., Bronowicki J.P., de Ledinghen V., et al. Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS). Lancet Infect Dis 2015, 15:397-404.
25. Feld J.J., Kowdley K.V., Coakley E., et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 2014, 370:1594-1603.
26. Ferenci P, Bernstein D., Lalezari J., PEARL-III Study, PEARL-IV Study, et al. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med 2014, 370:1983-1992.
27. Poordad F., Hezode C., Trinh R., et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med 2014, 370:1973-1982.
28. Sulkowski M.S., Gardiner D.F., Rodriguez-Torres M., AI444040 Study Group, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med 2014, 370:211-221. Available at:. http://www.nejm.org/doi/full/10.1056/NEJMoa1306218.
29. Jacobson I., Dore G.J., Foster G.R., et al. 1425 Simeprevir (TMC435) with peginterferon/ribavirin for chronic HCV genotype 1 infection in treatment naïve patients: results from QUEST-1, a phase III trial. J Hepatol 2013, 58:S574.
30. Manns M., Marcellin P., Poordad F.P., et al. 1413 Simeprevir (TMC435) with peginterferon/ribavirin for chronic HCV genotype 1 infection in treatment naïve patients: results from QUEST-2, a phase III trial. J Hepatol 2013, 58:S568.
31. Alqahtani S.A., Afdhal N., Zeuzem S., et al. Safety and tolerability of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic HCV genotype 1 infection: analysis of phase 3 ION trials. Hepatology 2015, 10.1002/hep.27890.
32. Kwo P, Gitlin N, Nahass R, et al. A phase 3, randomised, open-label study to evaluate the efficacy and safety of 12 and 8 weeks of simeprevir (SMV) plus sofosbuvir (SOF) in treatment-naive and -experienced patients with chronic HCV genotype 1 infection without cirrhosis: OPTIMIST-1. Program and abstracts of the 50th Annual Meeting of the European Association for the Study of the Liver. Vienna (Austria), April 22-26, 2015. Abstract LB14. Available at: . https://ilc-congress.eu/scientific-info/abstracts/.
33. Jacobson I.M., Ghalib R.H., Rodriguez-Torres M., et al. SVR results of a once-daily regimen of simeprevir (TMC435) plus sofosbuvir (GS-7977) with or without ribavirin in cirrhotic and non-cirrhotic HCV genotype 1 treatment-naive and prior null responder patients: the COSMOS study. Hepatology 2013, 58:1379A.
34. Afdhal N., Reddy K.R., Nelson D.R., et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014, 370:1483-1493. Available at:. http://www.nejm.org/doi/full/10.1056/NEJMoa1316366.
35. Andreone P., Colombo M.G., Enejosa J.V., et al. ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection. Gastroenterology 2014, 147:359-365.e1.
36. Zeuzem S., Jacobson I.M., Baykai T., et al. Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 2014, 370:1604-1614. Available at:. http://www.nejm.org/doi/full/10.1056/NEJMoa1401561.
37. van der Meer A.J., Veldt B.J., Feld J.J., et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 2012, 308:2584-2593.
38. Iacobellis A., Perri F., Valvano M.R., et al. Long-term outcome after antiviral therapy of patients with hepatitis C virus infection and decompensated cirrhosis. Clin Gastroenterol Hepatol 2011, 9:249-253.
39. Bourlière M, Sulkowski MS, Omata M, et al. An integrated safety and efficacy analysis of >500 patients with compensated cirrhosis treated with ledipasvir/sofosbuvir with or without ribavirin. Program and abstracts of the 65th Annual Meeting of the American Association for the Study of Liver Diseases. Boston (MA), November 7-11, 2014. Abstract 82.
40. Flamm SL, Everson GT, Charlton MR, et al. Ledipasvir/sofosbuvir with ribavirin for the treatment of HCV in patients with decompensated cirrhosis: preliminary results of a prospective, multicenter study. Program and abstracts of the 2014 Annual Meeting of the American Association for the Study of Liver Diseases. Boston (MA), November 7-11, 2014. Abstract 239.
41. Bourliere M, Bronowicki J, de Ledinghen V, et al. Ledipasvir/sofosbuvir fixed dose combination is safe and efficacious in cirrhotic patients who have previously failed protease-inhibitor based triple therapy. Program and abstracts of the 65th Annual Meeting of the American Association for the Study of Liver Diseases. Boston (MA), November 7-11, 2014. Abstract LB-6.
42. Poordad F, Schiff ER, Vierling JM, et al. Daclatasvir, sofosbuvir, and ribavirin combination for HCV patients with advanced cirrhosis or post-transplant recurrence: ALLY-1 phase 3 study. Program and abstracts of the 50th Annual Meeting of the European Association for the Study of the Liver. Vienna (Austria), April 22-26, 2015. Abstract L08. Available at: . https://ilc-congress.eu/scientific-info/abstracts/.
43. Lawitz E, Matusow G, DeJesus E, et al. A phase 3, open-label, single-arm study to evaluate the efficacy and safety of 12 weeks of simeprevir (SMV) plus sofosbuvir (SOF) in treatment-naive or -experienced patients with chronic HCV genotype 1 infection and cirrhosis: OPTIMIST-2. Program and abstracts of the 50th Annual Meeting of the European Association for the Study of the Liver. Vienna (Austria), April 22-26, 2015. Abstract LP04. Available at: . https://ilc-congress.eu/scientific-info/abstracts/.
44. Saxena V, Koraishy FM, Sise M, et al. Safety and efficacy of sofosbuvir-containing regimens in hepatitis C infected patients with reduced renal function: real world experience from HCV-TARGET. Program and abstracts of the 50th Annual Meeting of the European Association for the Study of the Liver. Vienna (Austria), April 22-26, 2015. Abstract LP08. Available at: . https://ilc-congress.eu/scientific-info/abstracts/.
45. Wyles D., Pockros P., Morelli G., et al. Ledipasvir-sofosbuvir plus ribavirin for patients with genotype 1 hepatitis C virus previously treated in clinical trials of sofosbuvir regimens. Hepatology 2015, 61(6):1793-1797.
46. Lawitz E, Flamm S, Yang JC, et al. Retreatment of patients who failed 8 or 12 weeks of ledipasvir/sofosbuvir-based regimens with ledipasvir/sofosbuvir for 24 weeks. Program and abstracts of the 50th Annual Meeting of the European Association for the Study of the Liver. Vienna (Austria), April 22-26, 2015. Abstract O005. Available at: . https://ilc-congress.eu/scientific-info/abstracts/.
47. Forns X., Gordon S.C., Zuckerman E., et al. Grazoprevir/elbasvir plus ribavirin for chronic HCV genotype-1 infection after failure of combination therapy containing a direct-acting antiviral agent. J Hepatol 2015, 10.1016/j.jhep.2015.04.009.
48. Ravi S., Nasiri-Toosi M., Karimzadeh I., et al. Pattern and associated factors of anti-hepatitis C virus treatment-induced adverse reactions. Expert Opin Drug Saf 2014, 13:277-286.
49. Koh C., Liang T.J. What is the future of ribavirin therapy for hepatitis C?. Antivir Res 2014, 104:34-39.
50. Rebetol [package insert]. Whitehouse station (NJ): Merck & Co, Inc; 2014.
51. Lawitz E., Gane E., Pearlman B., et al. Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patient with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial. Lancet 2014, 385(9973):1075-1086. Available at:. http://www.jwatch.org/na36381/2014/12/04/promising-all-oral-hcv-regimen-difficult-treat-groups#sthash.upvkVlyJ.dpuf.
52. Zeuzem S., Ghalib R., Reddy K.R., et al. Grazoprevir-elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic HCV genotype 1, 4, or 6 infection: a randomized trial. Ann Intern Med 2015, 10.7326/M15-0785.
53. Poordad F., Sievert W., Mollison L., UNITY-1 Study Group, et al. Fixed-dose combination therapy with daclatasvir, asunaprevir, and beclabuvir for noncirrhotic patients with HCV genotype 1 infection. JAMA 2015, 313:1728-1735.
54. Muir A.J., Poordad F., Lalezari J., et al. Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype 1 infection with compensated cirrhosis. JAMA 2015, 313:1736-1744.
55. Kohli A., Osinusi A., Sims Z., et al. Virological response after 6 week triple-drug regimens for hepatitis C: a proof-of-concept phase 2A cohort study. Lancet 2015, 385:1107-1113.
56. Gane EJ, Hyland RH, Tang Y, et al. Safety and efficacy of short-duration treatment with GS-9857 combined with sofosbuvir/GS-5816 in treatment-naive and DAA-experienced genotype 1 patients with and without cirrhosis. Program and abstracts of the 50th Annual Meeting of the European Association for the Study of the Liver. Vienna (Austria), April 22-26, 2015. Abstract LP03. Available at: . https://ilc-congress.eu/scientific-info/abstracts/.
57. Bush C.O., Pokrovskii M.V., Saito R., et al. A small-molecule inhibitor of hepatitis C virus infectivity. Antimicrob Agents Chemother 2014, 58(1):386-396.